Selinexor Treatment of Refractory Myeloma (STORM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02336815|
Recruitment Status : Active, not recruiting
First Posted : January 13, 2015
Last Update Posted : November 29, 2018
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Selinexor Drug: Dexamethasone||Phase 2|
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd), both dosed twice weekly in each four-week cycle, in patients with MM previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and daratumumab.
This study consists of two parts:
- Part 1 enrolled patients with both quad-refractory MM and penta-refractory MM.
- Part 2 will enroll patients with penta-refractory MM only.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||202 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-‑Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab|
|Study Start Date :||May 2015|
|Actual Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||October 2019|
Experimental: Selinexor & Dexamethasone
Selinexor 80 mg (45 mg/m2 BSA) plus low-dose Dexamethasone (20 mg), both twice weekly by mouth
Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
Other Name: KPT-330
20 mg will be given with each dose of Selinexor.
- Overall Response Rate [ Time Frame: 5-7 months ]Achievement of sCR, CR, VGPR, or PR for the overall evaluable population with supportive data provided by DOR (duration of response).
- Duration of Response [ Time Frame: 5-7 months ]The duration of time measured from when measurement criteria for response were first met until the date of first recurrence, PD or death)
- Clinical Benefit Rate [ Time Frame: 6 months ]Clinical Benefit Rate (CBR = sCR + CR + PR + Minor Response [MR]), and duration of CBR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336815
Show 55 Study Locations
|Study Director:||Michael Kauffman, MD, Ph.D||Karyopharm Therapeutics Inc|